Semaglutide — a glucagon-like peptide-1 receptor agonist (GLP-1 agonist) that’s the active ingredient in blockbuster anti-obesity drugs like Wegovy and Ozempic — may heighten taste sensitivity in women with obesity. New research from the University Medical Center in Ljubljana, Slovenia found that the tongue cells of patients who took semaglutide experienced changes in gene expression that’s responsible for the perception of taste, namely sweetness.
The recent findings have not yet been published in a peer-reviewed scientific journal. According to Medical News Today, the research was presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, on June 1.
